Elevation Oncology, Inc. ELEV
0.37 0.00 (+0.00%)
At closeJul 23, 2025, 4:00 PM EDT
0.365 Day range 0.365
0.44 52-week range 5.83
Analyst view
Consensus: strong buy
Strong buy
Price target (mean) 7.00 +1817.8% upside
Now 0.365
- Target (low)
- 5.00
- Target (mean)
- 7.00
- Target (high)
- 10.00
Ratings (0m) 7 7 buy · 0 hold · 0 sell
- Strong buy3
- Buy4
- Hold0
- Sell0
- Strong sell0
Recommendation trend
- This month 7
- 1 month ago 7
- 2 months ago 7
Earnings and revenue estimates
Consensus for the coming quarters and fiscal years
| Period | EPS estimate | Low – high | Year ago | EPS growth | Revenue estimate | Revenue growth | Analysts |
|---|---|---|---|---|---|---|---|
| Current quarter | -0.2075 | -0.23 – -0.15 | -0.19 | -9.2% | 0 | 0.0% | 4 |
| Next quarter | -0.205 | -0.23 – -0.18 | -0.20613 | +0.5% | 0 | 0.0% | 2 |
| Current year | -0.7925 | -0.85 – -0.69 | -1.19 | +33.5% | 0 | 0.0% | 4 |
| Next year | -0.8175 | -0.94 – -0.71 | -0.7925 | -3.1% | 0 | 0.0% | 4 |
Upgrades and downgrades
The latest rating changes
| Date | Firm | Action | From | To |
|---|---|---|---|---|
| Dec 19, 2024 | JMP Securities | Reiterated | Market Outperform | Market Outperform |
| Dec 13, 2024 | HC Wainwright & Co. | Reiterated | Buy | Buy |
| Dec 6, 2024 | Stephens & Co. | Reiterated | Overweight | Overweight |
| Aug 7, 2024 | HC Wainwright & Co. | Reiterated | Buy | Buy |
| Jul 15, 2024 | JMP Securities | Reiterated | Market Outperform | Market Outperform |
| Jun 28, 2024 | JMP Securities | Reiterated | Market Outperform | Market Outperform |
| May 31, 2024 | Piper Sandler | Initiated | — | Overweight |
| May 14, 2024 | Stephens & Co. | Initiated | — | Overweight |
| May 3, 2024 | Wedbush | Reiterated | Outperform | Outperform |
| Apr 9, 2024 | HC Wainwright & Co. | Reiterated | Buy | Buy |
| Mar 7, 2024 | JMP Securities | Reiterated | Market Outperform | Market Outperform |
| Mar 7, 2024 | Wedbush | Maintained | Outperform | Outperform |
| Mar 7, 2024 | HC Wainwright & Co. | Reiterated | Buy | Buy |
| Mar 1, 2024 | JMP Securities | Initiated | — | Market Outperform |
| Feb 20, 2024 | HC Wainwright & Co. | Maintained | Buy | Buy |
| Nov 6, 2023 | Wedbush | Reiterated | Outperform | Outperform |
| Sep 29, 2023 | HC Wainwright & Co. | Initiated | — | Buy |
| Jun 5, 2023 | Wedbush | Maintained | Outperform | Outperform |
| May 30, 2023 | SVB Securities | Upgrade | Market Perform | Outperform |
| Mar 10, 2023 | Wedbush | Reiterated | — | Outperform |
| Jan 9, 2023 | SVB Leerink | Maintained | — | Market Perform |
| Nov 10, 2022 | JP Morgan | Downgrade | Neutral | Underweight |
| Nov 7, 2022 | SVB Leerink | Downgrade | Outperform | Market Perform |
| Aug 8, 2022 | JP Morgan | Downgrade | Overweight | Neutral |
| Mar 4, 2022 | Wedbush | Maintained | — | Outperform |
| Dec 23, 2021 | HC Wainwright & Co. | Initiated | — | Buy |
| Jul 20, 2021 | Wedbush | Initiated | — | Outperform |
| Jul 20, 2021 | Cowen & Co. | Initiated | — | Outperform |
| Jul 20, 2021 | SVB Leerink | Initiated | — | Outperform |